Loading...
BLOG2021-01-21T12:21:19-05:00

Recent Posts

Archives

Tags

Latest from the NCI

  • Shorter, More Intensive Radiation Safe after Surgery for Prostate CancerShorter, More Intensive Radiation Safe after Surgery for Prostate Cancer
    Many with prostate cancer can safely receive shorter, higher-dose radiation therapy after surgery, a new study has found. The approach, called HYPORT, didn’t harm patients’ quality of life compared with the standard radiation approach, trial finds. Read more »
  • Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALLTecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL
    The CAR T-cell therapy Tecartus has become the first such treatment approved by FDA to treat adults with acute lymphoblastic leukemia (ALL). The approval is for patients whose cancer has not responded to treatment or returned after treatment. Read more »
  • New on NCI’s Websites for November 2021New on NCI’s Websites for November 2021
    NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of November 2021. Read more »
  • Studies Delve Deep into the Protein Machinery of Cancer CellsStudies Delve Deep into the Protein Machinery of Cancer Cells
    A research team has identified common interactions between cancer-related proteins in cancer cells. They also created a map of how these protein complexes function in those cells and identified a promising treatment target for head and neck cancer. Read more »
  • Does Too Much Fructose Help Colorectal Cancers Grow?Does Too Much Fructose Help Colorectal Cancers Grow?
    Excess fructose can promote obesity and colorectal cancer, a new study shows. In mice, the study found that the sweetener, a component of table sugar and high-fructose corn syrup, increased how long normal and cancer cells in the intestines live. Read more »
  • Adjuvant Immunotherapy Approved for Some Patients with Lung CancerAdjuvant Immunotherapy Approved for Some Patients with Lung Cancer
    Atezolizumab (Tecentriq) is now the first immunotherapy approved by FDA for use as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer. The approval was based on results of a clinical trial called IMpower010. Read more »
  • Despite Proven Safety of HPV Vaccines, More Parents Have ConcernsDespite Proven Safety of HPV Vaccines, More Parents Have Concerns
    Despite consistent evidence that HPV vaccines are safe and effective, a new study shows that more parents are citing concerns about their safety. Researchers cautioned that efforts are needed to counter this trend and improve vaccination rates. Read more »
  • Enhertu May Be Preferred Therapy for Some Metastatic Breast CancersEnhertu May Be Preferred Therapy for Some Metastatic Breast Cancers
    In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show. Read more »

CHANGE A LIFE TODAY

As long as cancer persists, none of us can truly rest. It doesn’t take much to change a life, Get in touch today and start making the difference.

Contact US
DONATE NOW
Go to Top